Crossover Randomized Controlled Trial
Also known as: crossover RCT, crossover trial, within-subject RCT, AB/BA crossover design
A crossover randomized controlled trial (crossover RCT) is an experimental design in which each participant receives all study interventions in a randomized sequence, separated by a washout period. Because every participant serves as their own control, within-subject variability is eliminated from the treatment comparison, yielding greater statistical power per participant than a parallel-group RCT of equal size.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
+13 more
When to use it
Use a crossover RCT when the condition being treated is stable and chronic (e.g., hypertension, chronic pain, asthma), when a sufficient washout period can be defined and enforced, and when sample size is limited — the within-subject design can require substantially fewer participants to achieve the same power as a parallel-group RCT. It is particularly well suited to pharmacokinetic studies, dose-finding trials, and health technology assessments comparing symptomatic treatments. Do NOT use a crossover design when: (1) the intervention is expected to produce a permanent or long-lasting change (e.g., surgery, vaccination, behaviour-change programs that persist); (2) the disease trajectory is rapidly progressive or highly variable between periods; (3) dropout rates are expected to be high, since incomplete crossover data are harder to analyse than parallel-group dropouts; or (4) the condition is acute and episode-based, making the second period incomparable to the first.
Strengths & limitations
- Each participant acts as their own control, eliminating between-subject variability from the treatment comparison and substantially increasing statistical power.
- Requires fewer participants than a parallel-group RCT to achieve equivalent power — an important advantage when participants are scarce or recruitment is costly.
- Participants and clinicians often find it attractive because every enrolled participant has the opportunity to receive the active intervention.
- Estimates of individual treatment responses can be obtained, enabling exploration of treatment-by-subject interactions.
- Well-established regulatory acceptance in pharmacological and device trials, with guidance from ICH E9 and EMA.
- Assumes no carryover: the validity of the entire design depends on a washout period long enough to eliminate residual treatment effects — this assumption can be hard to verify or guarantee.
- Period effects (secular trends, learning effects, disease progression) can confound within-subject comparisons if conditions change systematically across periods.
- Unsuitable for conditions that are acute, episodic, or likely to be cured or substantially altered by the first treatment.
- Longer trial duration due to multiple treatment periods and washout intervals increases dropout risk and participant burden.
- Statistical analysis is more complex than parallel-group RCTs; carryover testing has low power and a failed test does not prove absence of carryover.
Frequently asked
How do I determine the right washout period length?
The washout period should be at least five times the biological half-life of the intervention — for pharmacological agents this is typically straightforward to calculate. For non-drug interventions (e.g., dietary changes, physiotherapy) the appropriate length must be justified by pilot data or physiological reasoning. When in doubt, err on the side of a longer washout; a design with a demonstrably adequate washout is far more credible than one where carryover is merely hoped to be absent.
What happens if carryover is detected?
If the period-by-treatment interaction test is significant (indicating carryover), the second-period data are unreliable for the treatment comparison. The usual fallback is to restrict analysis to first-period data only, which converts the crossover into a parallel-group comparison with roughly half the intended sample — greatly reducing power. This outcome underlines the importance of an adequate washout period rather than relying on statistical testing to rescue a flawed design.
Is a crossover RCT always more efficient than a parallel-group RCT?
Not always. The efficiency advantage depends on the intra-subject correlation: the higher the within-person correlation of outcomes across periods (i.e., the more stable the condition), the greater the power gain. If outcomes are poorly correlated within individuals across time, the sample-size advantage shrinks. The additional complexity and dropout risk of multiple periods must also be factored into the efficiency calculation.
Can crossover RCTs have more than two periods?
Yes. Multi-period crossover designs (e.g., three or four treatments in Latin square or Williams square arrangements) are used when several interventions must be compared within each participant. These designs offer further efficiency gains but increase participant burden, dropout risk, and the complexity of carryover modelling. They are most common in pharmacokinetic and bioequivalence research.
How should I handle missing data when a participant drops out after period 1?
Participants who complete only period 1 provide usable data for that period and should not be excluded from the analysis. A pre-specified analysis plan using linear mixed models can incorporate all observed data under a missing-at-random assumption. Multiple imputation or sensitivity analyses under plausible missing-not-at-random assumptions should be considered when dropout is substantial.
Sources
- Senn, S. (2002). Cross-over Trials in Clinical Research (2nd ed.). Wiley. ISBN: 978-0471496533
- Jones, B., & Kenward, M. G. (2003). Design and Analysis of Cross-Over Trials (2nd ed.). Chapman and Hall/CRC. ISBN: 978-1584883429
How to cite this page
ScholarGate. (2026, June 3). Crossover Randomized Controlled Trial. ScholarGate. https://scholargate.app/en/experimental-design/crossover-randomized-controlled-trial
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Randomized Controlled TrialExperimental design↔ compare
- Blocked Randomized Controlled TrialExperimental design↔ compare
- Factorial Randomized Controlled TrialExperimental design↔ compare
- Latin Square DesignExperimental design↔ compare
- Randomized Controlled TrialExperimental design↔ compare